The 2021 ADA Standards of Medical Care in Diabetes further refined these recommendations, emphasizing the importance of SGLT2 inhibitors and GLP-1RAs in specific high-risk patient populations [7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.